Cat. No. 1646
Alternative Name: AF 1890
Chemical Name: 1-[(2,4-Dichlorophenyl)methyl]-1H-i
Biological ActivityAnticancer and antispermatogenic agent in vitro and in vivo. Inhibits cellular energy metabolism in some cells via inhibition of mitochondrial hexokinase. Also blocks CFTR Cl- channels in vitro.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Lobl et al (1981) Effects of lonidamine (AF 1890) and its analogues on follicle-stimulating hormone, luteinizing hormone, testosterone and rat androgen binding protein concentrations in the rat and rhesus monkey. Chemotherapy 27 61. PMID: 6793318.
De Martino et al (1984) Effects of lonidamine on murine and human tumor cells in vitro. A morphological and biochemical study. Oncology 41 15. PMID: 6717891.
Teiche (1994) Lonidamine: in vitro/in vivo correlations. Eur.J.Cancer 30A 1411. PMID: 7833093.
Gong et al (2002) Mechanism of lonidamine inhibition of the CFTR chloride channel. Br.J.Pharmacol. 137 928. PMID: 12411425.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Lonidamine, supplier, Mitochondrial, hexokinase, inhibitors, CFTR, Cl-, chloride, channels, blockers, Carbohydrate, Metabolism, Kinases, AF1890
Find multiple products by catalog number
New Products in this Area
Salt inducible kinase (SIK) inhibitorLDN 209929 dihydrochloride
Potent and selective haspin kinase inhibitorRKI 1447 dihydrochloride
Potent and selective ROCK inhibitor; antitumorLIMKi 3
Potent LIM kinase inhibitor; antitumorFRAX 486
Potent p21-activated kinase (PAK) inhibitor; brain penetrant and orally bioavailableBIX 02189
Selective MEK5 and ERK5 inhibitorTC Mps1 12
Potent and selective monopolar spindle 1 (Mps1) kinase inhibitor; orally activeGSK 2606414
Potent and selective PERK inhibitor; orally bioavailableAZ 20
Potent and selective ATR kinase inhibitor; antitumorAZD 7762 hydrochloride
Potent and selective ATP-competitive inhibitor of Chk1 and Chk2PHT 427
Dual Akt and PDK1 inhibitor; antitumorML 786 dihydrochloride
Potent Raf kinase inhibitor; orally bioavailableSenexin A
Cyclin-dependent kinase 8 (cdk8) inhibitorXL 388
Potent and selective mTOR inhibitor; antitumorPS 1145 dihydrochloride
Selective IKK inhibitor; orally activeRSVA 405
AMPK activatorAtiprimod dihydrochloride
JAK2 inhibitorAIM 100
Potent and selective Ack1 inhibitorML 120B dihydrochloride
Novel IKK2-selective inhibitorML 202
Pyruvate kinase M2 activator
November 15 - 19, 2014
Washington D.C., USA